Table 2.
Number of confirmed COVID- 19 in patients with hemoglobinopathies reported from 6 countries in comparison to the number of patients in the general population, updated to 8th June 2020 (https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases).
| Countries and number of participating Centers | Number of patients with hemoglobinopathies: TM - TI and SCD | Number (%) of confirmed Covid-19 positive cases in patients with hemoglobinopathies | Number of Covid-19 positive cases in general population |
|---|---|---|---|
| Italy (3 Centers) | 306 - 79 – 37 | 1 TM (F - 34 yrs) (0.3 %) | 234,998 |
| Turkey (5 Centers) | 658 -164 -335 |
1 TM (M - 22 yrs); 1 TM asymptomatic (F - 30 yrs) (0.3 %) |
170,132 |
| Azerbaijan (1 Center) | 1,304 - 605 -124 | 2 TM asymptomatic (1 F - 29 yrs and 1M - 31 yrs) (0.15 %) | 7,553 |
| Iran (1 Center) | 720 - 311- 0 |
3 TM (F - 30, 31 and 38 yrs) (0.41 %) 1 TI (F- 66 yrs) (0.32 %) |
171,789 |
| Cyprus (1 Center) | 247- 44 – 28 | 1 TM (M - 46 yrs) (0.4%) | 964 |
| Oman (1 Center) | 300 - 44 – 2,000 | 3 SCD (2 F -13 and 43 yrs, and 1 M -26 yrs) (0.15%) | 16,882 |
Legend. TM:Thalassemia major; TI: Thalassemia intermedia; SCD: Sickle cell disease; M: males; F: females.